[{"address1": "780 Brannan Street", "city": "San Francisco", "state": "CA", "zip": "94103", "country": "United States", "phone": "415-651-3316", "website": "https://olema.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sean P. Bohen M.D., Ph.D.", "age": 56, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1150370, "exercisedValue": 0, "unexercisedValue": 12082278}, {"maxAge": 1, "name": "Mr. Shane William Charles Kovacs M.B.A.", "age": 49, "title": "Chief Operating & Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 820370, "exercisedValue": 0, "unexercisedValue": 723488}, {"maxAge": 1, "name": "Dr. Naseem  Zojwalla M.D.", "age": 50, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 753370, "exercisedValue": 0, "unexercisedValue": 727575}, {"maxAge": 1, "name": "Mr. Geoffrey  Mogilner", "title": "Vice President of Investor Relations & Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Julie  Dexter", "title": "Senior VP & Head of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David C. Myles Ph.D.", "age": 60, "title": "Chief Discovery & Non-Clinical Development Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 200000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Demiana  Faltaos Ph.D., Pharm.D.", "title": "VP & Head of Clinical Pharmacology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John B. Moriarty Jr., J.D.", "age": 55, "title": "Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 434324, "exercisedValue": 0, "unexercisedValue": 10904116}, {"maxAge": 1, "name": "Ms. Sasha  Austin CPA", "title": "VP of Finance & Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 13.99, "open": 13.87, "dayLow": 13.22, "dayHigh": 14.45, "regularMarketPreviousClose": 13.99, "regularMarketOpen": 13.87, "regularMarketDayLow": 13.22, "regularMarketDayHigh": 14.45, "beta": 2.104, "forwardPE": -5.4163427, "volume": 1454082, "regularMarketVolume": 1454082, "averageVolume": 1010417, "averageVolume10days": 1776070, "averageDailyVolume10Day": 1776070, "bid": 13.85, "ask": 13.96, "bidSize": 200, "askSize": 200, "marketCap": 778598528, "fiftyTwoWeekLow": 6.03, "fiftyTwoWeekHigh": 17.791, "fiftyDayAverage": 10.4352, "twoHundredDayAverage": 12.265525, "currency": "USD", "enterpriseValue": 531269184, "floatShares": 28283775, "sharesOutstanding": 55933800, "sharesShort": 8539476, "sharesShortPriorMonth": 8974804, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1527, "heldPercentInsiders": 0.03813, "heldPercentInstitutions": 1.01793, "shortRatio": 11.5, "shortPercentOfFloat": 0.2699, "bookValue": 4.228, "priceToBook": 3.2923367, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -99339000, "trailingEps": -2.0, "forwardEps": -2.57, "enterpriseToEbitda": -4.738, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "OLMA", "underlyingSymbol": "OLMA", "shortName": "Olema Pharmaceuticals, Inc.", "longName": "Olema Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1605796200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "435c746d-8ba5-3a9e-8724-ea5906efb2d8", "gmtOffSetMilliseconds": -14400000, "currentPrice": 13.92, "targetHighPrice": 30.0, "targetLowPrice": 20.0, "targetMeanPrice": 27.29, "targetMedianPrice": 29.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 248976992, "totalCashPerShare": 4.454, "ebitda": -112133000, "totalDebt": 2209000, "quickRatio": 9.52, "currentRatio": 9.613, "debtToEquity": 0.935, "returnOnAssets": -0.30606002, "returnOnEquity": -0.48306, "freeCashflow": -45569248, "operatingCashflow": -86832000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-06"}]